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Hypokalemia in the elderly is usually due to gastro-
intestinal loss or the administration of diuretics. Hyper-
tension in the elderly is usually assumed to be essential
primary hypertension, and the cause is not defined1.
However, the association of hypertension, unexplained
hypokalemia, and metabolic alkalosis should raise the
possibility of secondary hypertension caused by over-
production of aldosterone.
We present an elderly patient with hypertension who
was admitted with a brainstem infarction and found to
have hypokalemia, prompting a search for the cause.
Case Report
A 63-year-old Chinese man complained of right-sided
clumsiness, slurred speech, and general weakness on the
day of admission. He had no recent history of vomit-
ing or diarrhea. He had had hypertension for 5 years
that was treated with an unknown medication. He
admitted that his blood pressure was poorly controlled.
He had no other known illnesses but had been a heavy
smoker for more than 15 years. He denied use of any
other medications. On admission, his blood pressure
was 184/64 mmHg, and he was alert, although his
speech was slurred. Examination of the chest, heart
and abdomen were unremarkable. Neurologic exami-
nation disclosed right hemiplegia. The electrocardio-
gram revealed normal sinus rhythm. He was found to be
markedly hypokalemic (serum potassium, 1.9mEq/L),
but the serum sodium (145 mEq/L), blood urea nitrogen
(10 mg/dL) and creatinine (0.9 mg/dL) were within nor-
mal limits. Magnetic resonance imaging and angiogra-
phy of the brain disclosed a recent ischemic infarct
involving the ventral pons secondary to occlusion of
the midbasilar artery. Echocardiography revealed no
evidence of intracardiac thrombus. Amlodipine 5 mg
was given daily to control the blood pressure, and
potassium chloride was given by slow intravenous
infusion, which raised the serum potassium level to
3.0 mEq/L. This was then switched to oral potassium
30 mEq daily, but the serum potassium remained at
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2.5 to 2.6 mEq/L. Further investigation was undertaken
to investigate the hypokalemia.
The spot urine potassium indicated hyperkaliuresis,
and the patient had metabolic alkalosis with normal
peripheral plasma renin activity (PRA) and an elevated
plasma aldosterone concentration (PAC) (Table). Abdo-
minal computed tomography was then performed to
identify the source of the hyperaldosteronism. The
hypodense adrenal glands were enlarged bilaterally to
about 2 cm, and the radiologist suggested that there
might be bilateral adrenal adenomas (Figure 1). Magnetic
resonance imaging and magnetic resonance angio-
graphy of the renal arteries also demonstrated bilat-
eral adrenal enlargement with normal renal arteries
(Figure 2). Serial nuclear medicine scans were performed
for 4 days following intravenous injection of 131I-labeled
6-beta-iodomethyl-19-norcholesterol (NP-59), while the
patient was given dexamethasone. This revealed faint
visualization of the adrenal glands on the third day
and clearer visualization on the fourth day, consistent
with bilateral adrenal hyperplasia (Figure 3).
Spironolactone 150 mg daily was begun and then
tapered to 50 mg daily. The hypokalemic metabolic
alkalosis subsequently resolved without the need for
further potassium replacement. The patient’s blood
pressure was also easily controlled with the combina-
tion of spironolactone and amlodipine 5 mg daily.
Discussion
This elderly patient’s hypertension, hypokalemia, and
metabolic alkalosis were due to overproduction of
aldosterone, in this case by hyperplasia of the adrenal
Table. Laboratory evaluation of persistent hypokalemia in a patient with hypertension
Patient’s value Reference value
Urine output (mL/day) 2,100
TTKG 8.9 < 3
Serum osmolality (mOsm/kg) 295 285–295
Urine osmolality (mOsm/kg) 351 300–900
Spot urine potassium (mEq/L) 27.6 < 15
Supine PAC (pg/mL) 322 29–162
Supine PRA (pg/mL) 3.49 1.1–20
Cortisol at 8 a.m. (µg/dL) 17.5 5–25
24 hr urine VMA (mg/day) 6.0 1.0–7.5
pH 7.492 7.38–7.44
PaCO2 (mmHg) 39.1 35–45
Bicarbonate (mmol/L) 29.2 21–28
TTKG = transtubular potassium concentration gradient; PAC = plasma aldosterone concentration; PRA = peripheral plasma renin activity;
VMA = vanillymandelic acid; PaCO2 = arterial carbon dioxide partial pressure.
Figure 1. Computed tomography of the abdomen demon-
strating bilaterally enlarged, hypodense adrenal glands
measuring about 2 cm (white arrows).
Figure 2. Low signal intensity seen in bilaterally enlarged
adrenal masses on T1- and T2-weighted images with signal
loss on out-of-phase images (white arrow).
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glands. The case illustrates the diagnostic approach in
patients with this constellation of findings. It is also a
good reminder that while such disorders are common,
we should be alert for the occasional patient who
presents with an unexpected disorder. It is rare to find
a secondary cause of hypertension in the elderly, but
our patient’s findings gave important clues that led to
the correct diagnosis.
A careful medication history is always important,
particularly in the elderly who are taking many differ-
ent drugs, a number of which can contribute to hypo-
kalemia. Certain medications, such as β2 agonists,
theophylline, chloroquine and laxatives, cause potas-
sium to shift into cells with resulting low serum levels.
Other medications, such as aldosterone analogues, hydro-
cortisone, aminoglycosides, cisplatin, carbenoxolone,
glycyrrhizic acid (the active agent of licorice) and a
number of diuretics, cause hypokalemia secondary to
increased potassium excretion. As is unfortunately
often the case, our patient did not know what medica-
tion he was taking for his hypertension, so we did not
know if he had been on a diuretic.
The key turning point in his course was discovering
that his hypokalemia was resistant to potassium re-
placement. The next step was then to determine if he
was excreting excess potassium in his urine. Hyper-
kaliuresis is defined as a urine potassium excretion of
more than 25 to 30 mEq/day2, a transtubular potas-
sium gradient (TTKG) of more than 3.0, or a spot urine
potassium to creatinine ratio of more than 2.0. These
tests are helpful, although the limitations must be
kept in mind. Incomplete urine collection, intracellular
potassium shift or interference by drugs may affect the
results of a 24-hour urine collection. Variations in muscle
mass, severe rhabdomyolysis, volume depletion, variable
urine volumes, and renal impairment may influence the
result of the spot urine potassium-to-creatinine ratio.
While a TTKG of greater than 3 indicates hyperkaliuresis
Day 0 Day 1
Day 3 Day 4
Figure 3. Serial scintigraphic scans from day 1 to day 4 after intravenous injection of 131I-6-beta-iodomethyl-19-norcholesterol
(NP-59) with dexamethasone suppression revealing faint visualization of the adrenal glands bilaterally on day 3 and greater
visibility on day 4 (white arrows), compatible with bilateral adrenal hyperplasia.
in patients with normal to high urine osmolality, it is
less reliable in those with low urine osmolality3. Our
patient’s 24-hour potassium excretion was nearly 58mEq
and his TTKG was 8.9 in the presence of normal serum
osmolality, so the diagnosis of hyperkaliuresis in his
case was clear.
According to a new diagnostic algorithm for evalu-
ating hypokalemia2, once hyperkaliuresis has been
demonstrated in a patient with hypertension and meta-
bolic alkalosis, the PAC and PRA levels are measured
and an aldosterone-to-renin ratio (ARR) calculated. An
ARR of greater than 30 is suggestive of primary aldos-
teronism, but values between 20 and 35 constitute a
“gray zone”4. There are several caveats to keep in mind
when interpreting the ratio, including the patient’s pos-
ture when the blood is drawn, the timing of the test,
medications, extremely low PRA, and age4. In patients
with extremely low PRA (less than 0.1 ng/mL/hour),
some authors suggested that an ARR of more than 20
in combination with a PAC greater than 15 ng/dL consti-
tute a positive result in positive screening for primary
aldosteronism4. False positives have been attributed to
treatment with β-blockers, methyldopa or clonidine,
chronic renal failure, potassium loading, and Gordon’s
syndrome, while a falsely negative ARR may be seen dur-
ing treatment with diuretics (including spironolactone)
and calcium channel blockers (especially dihydropy-
ridines), severe dietary salt restriction, renovascular
hypertension, pregnancy, and malignant hypertension5.
There is some disagreement, however, on whether anti-
hypertensive medications, including β-blockers, calcium
channel blockers, angiotensin-converting enzyme
inhibitors, aldosterone antagonist and diuretics, must
be discontinued before the test is performed6.
Since the ARR is only a screening test, some authors
recommend that confirmatory tests be required to
diagnose or exclude primary aldosteronism4. These
include a fludrocortisone or dexamethasone suppres-
sion test and an oral or intravenous saline loading
test. The fludrocortisone suppression test is reportedly
more reliable than a saline loading test7 and is positive
if aldosterone levels are higher than 5 ng/dL and PRA
levels less than 1.0 ng/mL/hour after administration of
fludrocortisone. The complexity and costs associated
with the confirmatory tests have led some experts to
suggest a trial of an aldosterone antagonist first, with
other studies undertaken only if this treatment fails.
However, this treatment is not without side effects,
including hyperkalemia, gynecomastia and prerenal
azotemia, so others would recommend confirmation
of the diagnosis and identification of the source5.
By definition, primary hyperaldosteronism is 
the overproduction of aldosterone due to adrenal
aldosterone-producing tumor or hyperplasia in the
absence of an elevated PRA. This is in contrast to sec-
ondary aldosteronism caused by elevated renin levels,
as seen in malignant hypertension, renal artery steno-
sis, renin-secreting tumor, and pheochromocytoma.
The prevalence of primary aldosteronism in an unse-
lected hypertensive population is around 5% to 40%8.
Although hypokalemia is a hallmark of primary aldos-
teronism, a reported 7% to 38% of patients with pri-
mary aldosteronism have normokalemia9. This makes
hyperaldosteronism particularly difficult to detect in
the elderly, as the normal potassium level would not
prompt a search for a secondary cause of hypertension.
Causes of primary aldosteronism include adrenal car-
cinoma (quite rare but suspected when an adrenal
tumor is larger than 4 cm), familial hyperaldosteronism
types I and II, adrenal hyperplasia, and aldosterone-
producing adenoma10. Adenoma has conventionally
thought to be the most common cause of primary
aldosteronism, but bilateral adrenal hyperplasia is in-
creasingly being recognized as a fairly frequent entity11,
although this may simply reflect a more precise case
finding rather than a true increased incidence. Adeno-
mas are commonly seen in middle-aged people who
have hypokalemia, minimal aldosterone suppressibility
by volume loading, increased body sodium content, and
an inverse relationship between aldosterone and angio-
tensin. Bilateral adrenal hyperplasia is seen more com-
monly in the elderly, in whom hypokalemia may not be
as prevalent. The aldosterone is often partially suppress-
ible with volume loading, the total sodium content is
normal, and there is a direct relation between aldoste-
rone and angiotensin8. The definitive test to distinguish
between an aldosterone-producing adenoma and bilat-
eral adrenal hyperplasia is adrenal venous sampling8,
which can detect adrenal adenomas of less than 1cm or
tumors that may be too small to be identified on con-
ventional imaging. The distinction between an adenoma
and bilateral hyperplasia is a vital one, as the former is
treated surgically, while the latter is not. However, in
some cases, it may be wise to proceed directly to a trial
of an aldosterone antagonist, reserving venous sampling
for those who fail to respond to medical treatment5.
Our patient had a very high ARR and did respond
very well to spironolactone. We did give dexamethasone
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to suppress his adrenal glands, but only as part of the
nuclear medicine study, which helped to confirm the
diagnosis of bilateral adrenal hyperplasia. Adrenal
venous sampling was not necessary in his case.
In our patient, the presence of hypertension and
hypokalemia that was unresponsive to potassium
replacement was the key to diagnosing his primary
aldosteronism. His metabolic abnormalities prompted
testing which demonstrated hyperkaliuresis, and the
subsequent investigations were straightforward. The
challenge, of course, is deciding whether to screen
elderly patients with hypertension who are not hypo-
kalemic, as recommended by some authors11.
References
1. Fisher ND, Williams GH. Hypertensive vascular disease. In:
Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL,
Jameson JL, eds. Harrison’s Principles of Internal Medi-
cine, 16th edition. New York: McGraw-Hill, 2005; 1463–80.
2. Cely CM, Contreras G. Approach to the patient with
hypertension, unexplained hypokalemia, and metabolic
alkalosis. Am J Kidney Dis 2001; 37: E24.
3. Lin SH, Lin YF, Chen DT, Chu P, Hsu CW, Halperin ML.
Laboratory tests to determine the cause of hypokalemia
and paralysis. Arch Intern Med 2004; 164: 1561–6.
4. Stowasser M, Gordon RD. The aldosterone–renin ratio in
screening for primary aldosteronism. Endocrinologist
2004; 14: 267–76.
5. Stowasser M, Gordon RD. Prevalence and diagnostic
workup of primary aldosteronism: new knowledge and
new approaches. Nephrol 2001; 6: 119–26.
6. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC.
Screening for primary aldosteronism without discontin-
uing hypertensive medications: plasma aldosterone-
renin ratio. Am J Kidney Dis 2001; 37: 699–705.
7. Khosla N, Hogan D. Mineralocorticoid hypertension and
hypokalemia. Semin Nephrol 2006; 26: 434–40.
8. Kaplan NM. The current epidemic of primary aldostero-
nism: causes and consequences. J Hypertens 2004; 22:
863–9.
9. Stowasser M, Gordon RD. Primary aldosteronism: learning
from the study of familial varieties. J Hypertens 2000;
18: 1165–76.
10. Plouin PF, Amar L, Chatellier G. Trends in the preva-
lence of primary aldosteronism, aldosterone-producing
adenomas, and surgically correctable aldosterone-
dependent hypertension. Nephrol Dial Transplant
2004; 19: 774–7.
11. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC,
Ward G, Archibald C, et al. High rate of detection of
primary aldosteronism, including surgically treatable
forms, after ‘non-selective’ screening of hypertensive
patients. J Hypertens 2003; 21: 2149–57.
